ASCO 2026: Celcuity CEO Brian Sullivan discusses the late breaking data for the PAM inhibitor gedatolisib that was just presented at ASCO - doubled the likelihood of survival in HR+/HER2- breast
These data were for patients with the PIK3CA mutation. The median PFS for the gedatolisib triplet combo was 11.1 months versus 5.6 months, compared to alpelisib plus fulvestrant.










.png)